

**Glenn Saldanha**  
Chairman & Managing Director

April 1, 2026

To,  
The Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

**Subject: Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

I hereby declare that, No Promoter/ Promoter Group along with persons acting in concert, has made any encumbrance, directly or indirectly during the financial year ended 2025-26.

Thanking you,

Yours Faithfully,



**Glenn Saldanha**  
Authorised Signatory

CC: To,  
All Members / Invitees,  
Audit Committee  
Glenmark Pharmaceuticals Limited  
B/2, Mahalaxmi Chambers,  
22, Bhulabhai Desai Road, Mumbai: 400 026